docetaxel + BMS-986218

**docetaxel + BMS-986218** is an investigational combination therapy for advanced or metastatic solid tumors, specifically being studied in metastatic castration-resistant prostate cancer (mCRPC). Docetaxel is a standard chemotherapy agent that acts as a microtubule inhibitor, disrupting cell division. BMS-986218 is a next-generation, non-fucosylated monoclonal antibody targeting cytotoxic T-lymphocyte-associated antigen 4 (CTLA4), designed to enhance immune-mediated anti-tumor effects through checkpoint inhibition and increased antibody-dependent cell cytotoxicity. The primary rationale for the combination is to pair the cytotoxic effect of docetaxel with the immune-stimulatory (checkpoint blockade) actions of BMS-986218 in enhancing anti-tumor responses. This combination is being developed and studied by Bristol Myers Squibb in multi-center clinical trials, and neither agent in this exact combination is currently approved for this indication[1][3][5][6].